Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 2Paraganglioma 2Gastro-enteropancreatic neuroendocrine tumor 2Vipoma 1Thymus Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Insulinoma 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

fluorodopa F 18 4Temozolomide 2Leucovorin 2Fluorouracil 2Everolimus 2Capecitabine 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1vatalanib 1regorafenib 1pentetreotide 1pasireotide 1Thalidomide 1Surgical Procedures, Operative 1Solutions 1Saline Solution 1Panobinostat 1Oxaliplatin 1Octreotide 1Observation 1Irinotecan 1Injections 1High-Energy Shock Waves 1Doxorubicin 1Bortezomib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Insulinoma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡